Searched for: in-biosketch:true
person:loebs01
Reply by Authors [Comment]
Cooley, Lauren Folgosa; Emeka, Adaeze A; Meyers, Travis J; Cooper, Phillip R; Lin, Daniel W; Finelli, Antonio; Eastham, James A; Logothetis, Christopher J; Marks, Leonard S; Vesprini, Danny; Goldenberg, S Larry; Higano, Celestia S; Pavlovich, Christian P; Chan, June M; Morgan, Todd M; Klein, Eric A; Barocas, Daniel A; Loeb, Stacy; Helfand, Brian T; Scholtens, Denise M; Witte, John S; Catalona, William J
PMID: 34503354
ISSN: 1527-3792
CID: 5061292
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort
Cooley, Lauren Folgosa; Emeka, Adaeze A; Meyers, Travis J; Cooper, Phillip R; Lin, Daniel W; Finelli, Antonio; Eastham, James A; Logothetis, Christopher J; Marks, Leonard S; Vesprini, Danny; Goldenberg, S Larry; Higano, Celestia S; Pavlovich, Christian P; Chan, June M; Morgan, Todd M; Klein, Eric A; Barocas, Daniel A; Loeb, Stacy; Helfand, Brian T; Scholtens, Denise M; Witte, John S; Catalona, William J
PURPOSE:We examined the demographic and clinicopathological parameters associated with the time to convert from active surveillance to treatment among men with prostate cancer. MATERIALS AND METHODS:A multi-institutional cohort of 7,279 patients managed with active surveillance had data and biospecimens collected for germline genetic analyses. RESULTS:Of 6,775 men included in the analysis, 2,260 (33.4%) converted to treatment at a median followup of 6.7 years. Earlier conversion was associated with higher Gleason grade groups (GG2 vs GG1 adjusted hazard ratio [aHR] 1.57, 95% CI 1.36-1.82; ≥GG3 vs GG1 aHR 1.77, 95% CI 1.29-2.43), serum prostate specific antigen concentrations (aHR per 5 ng/ml increment 1.18, 95% CI 1.11-1.25), tumor stages (cT2 vs cT1 aHR 1.58, 95% CI 1.41-1.77; ≥cT3 vs cT1 aHR 4.36, 95% CI 3.19-5.96) and number of cancerous biopsy cores (3 vs 1-2 cores aHR 1.59, 95% CI 1.37-1.84; ≥4 vs 1-2 cores aHR 3.29, 95% CI 2.94-3.69), and younger age (age continuous per 5-year increase aHR 0.96, 95% CI 0.93-0.99). Patients with high-volume GG1 tumors had a shorter interval to conversion than those with low-volume GG1 tumors and behaved like the higher-risk patients. We found no significant association between the time to conversion and self-reported race or genetic ancestry. CONCLUSIONS:A shorter time to conversion from active surveillance to treatment was associated with higher-risk clinicopathological tumor features. Furthermore, patients with high-volume GG1 tumors behaved similarly to those with intermediate and high-risk tumors. An exploratory analysis of self-reported race and genetic ancestry revealed no association with the time to conversion.
PMID: 34503355
ISSN: 1527-3792
CID: 5039392
TikTok and Prostate Cancer: Misinformation and Quality of Information using Validated Questionnaires
Xu, Alex J; Taylor, Jacob; Gao, Tian; Mihalcea, Rada; Perez-Rosas, Veronica; Loeb, Stacy
TikTok is a social network launched in 2016, which is used to create and share short videos (≤60 seconds). TikTok was the most downloaded app in the U.S. in 2018 and 2019 and is currently available in >55 countries. Similar to other social networks, TikTok users can follow other content creators and view a feed of videos. Users may associate their videos with captions and hashtags, and comment on others' videos. TikTok has 800 million total active users with >1 billion videos viewed daily.[1].
PMID: 33811424
ISSN: 1464-410x
CID: 4840912
Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis
Loeb, Stacy; Massey, Philip; Leader, Amy E; Thakker, Sameer; Falge, Emily; Taneja, Sabina; Byrne, Nataliya; Rose, Meredith; Joy, Matthew; Walter, Dawn; Katz, Matthew S; Wong, Risa L; Selvan, Preethi; Keith, Scott W; Giri, Veda N
BACKGROUND:Genetic testing, particularly for BRCA1/2, is increasingly important in prostate cancer (PCa) care, with impact on PCa management and hereditary cancer risk. However, the extent of public awareness and online discourse on social media is unknown, and presents opportunities to identify gaps and enhance population awareness and uptake of advances in PCa precision medicine. OBJECTIVE:The objective of this study was to characterize activity and engagement across multiple social media platforms (Twitter, Facebook, and YouTube) regarding BRCA and genetic testing for PCa compared with breast cancer, which has a long history of public awareness, advocacy, and prominent social media presence. METHODS:The Symplur Signals online analytics platform was used to obtain metrics for tweets about (1) #BRCA and #breastcancer, (2) #BRCA and #prostatecancer, (3) #genetictesting and #breastcancer, and (4) #genetictesting and #prostatecancer from 2016 to 2020. We examined the total number of tweets, users, and reach for each hashtag, and performed content analysis for a subset of tweets. Facebook and YouTube were queried using analogous search terms, and engagement metrics were calculated. RESULTS:During a 5-year period, there were 10,005 tweets for #BRCA and #breastcancer, versus 1008 tweets about #BRCA and #prostatecancer. There were also more tweets about #genetictesting and #breastcancer (n=1748), compared with #genetic testing and #prostatecancer (n=328). Tweets about genetic testing (12,921,954) and BRCA (75,724,795) in breast cancer also had substantially greater reach than those about PCa (1,463,777 and 4,849,905, respectively). Facebook groups and pages regarding PCa and BRCA/genetic testing had fewer average members, new members, and new posts, as well as fewer likes and followers, compared with breast cancer. Facebook videos had more engagement than YouTube videos across both PCa and breast cancer content. CONCLUSIONS:There is substantially less social media engagement about BRCA and genetic testing in PCa compared with breast cancer. This landscape analysis provides insights into strategies for leveraging social media platforms to increase public awareness about PCa germline testing, including use of Facebook to share video content and Twitter for discussions with health professionals.
PMCID:8550715
PMID: 34542414
ISSN: 2369-1999
CID: 5067312
A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines
Bhatt, Nikita R; Czarniecki, Stefan W; Borgmann, Hendrick; van Oort, Inge M; Esperto, Francesco; Pradere, Benjamin; van Gurp, Mark; Bloemberg, Jarka; Darraugh, J; Rouprêt, Morgan; Loeb, Stacy; N'Dow, James; Ribal, Maria J; Giannarini, Gianluca
CONTEXT/BACKGROUND:Clinical practice guideline (CPG) uptake does not occur spontaneously and requires active implementation, especially for long-term implementation. Social media (SoMe) with its power of rapid and global information exchange among physicians, patients, organizations, and stakeholders in the medical field can open up unprecedented opportunities for CPG dissemination. OBJECTIVE:The aim of this review was to assess the current use of SoMe in CPG dissemination across different medical specialties. EVIDENCE ACQUISITION/METHODS:A systematic review (SR) of the literature was conducted using Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Medline, Embase, and Cochrane databases and the general platform Google were searched for all relevant publications (no limitation for publication time and no language restrictions). The search revealed 1881 citations; following title and abstract review, 22 studies were identified; and five studies were finally included after full-text review. EVIDENCE SYNTHESIS/RESULTS:All included studies were published in the past 5 yr; there was a significant improvement in knowledge, awareness, compliance, and positive behavior toward CPGs with the use of SoMe dissemination compared with traditional methods. A large audience (healthcare professionals and patients) viewed and engaged with the SoMe process of CPG dissemination, and expressed an intent to engage in this method in the future. The studies included in the SR reported variable methods of SoMe use and similarly variable methods of analyzing the outcomes. CONCLUSIONS:Owing to the recent application of SoMe in the context of CPG dissemination, there is no standardized format for its use, and the data available are variable and limited. However, encouraging preliminary results have been reported using SoMe for CPG dissemination in multiple fields, and we have provided a pragmatic method of SoMe usage in CPG dissemination based on the review. It is vital to ensure a uniform method of application and assessment of SoMe use in CPG dissemination and implementation going forward. PATIENT SUMMARY/RESULTS:Social media (SoMe) plays an important role in rapid and global information exchange among physicians, patients, organizations, and stakeholders in the medical field, and its power can be harnessed in the dissemination of evidence-based clinical practice guidelines (CPGs) that guide clinicians in practice. Our review reveals that SoMe use for CPG dissemination is a relatively new concept published approximately 5 yr ago, and it has led to significant improvement in knowledge, awareness, compliance, and positive behavior with respect to the CPGs compared with traditional methods. A large audience (healthcare professionals and patients) viewed and engaged with the SoMe process. We have produced a pragmatic method of using SoMe in CPG dissemination. Considering the importance of CPGs in practice and the ever increasing role of SoMe in the medical profession, a new role for SoMe in CPG dissemination could be established.
PMID: 33172773
ISSN: 2405-4569
CID: 5209492
An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts
Herbert, Amber S; Nemirovsky, Amy; Hess, Deborah S; Walter, Dawn; Abraham, Nitya E; Loeb, Stacy; Malik, Rena D
OBJECTIVE:To evaluate the readability, quality, and accuracy of pelvic organ prolapse (POP) YouTube transcripts. METHODS:We analyzed the readability of written transcripts for the first 100 YouTube videos about "Pelvic Organ Prolapse." Transcripts were excluded if they lacked narration in English or contained both no text and no audio. Readability was evaluated using an online software (www.readabilityformulas.com) to determine reading grade levels. The quality of videos was scored using the DISCERN quality criteria and the Patient Education Materials Assessment Tool. Accuracy was assessed by comparing content to accepted POP treatment guidelines. RESULTS:The median grade level of all 100 videos was 12.6. High quality transcripts or transcripts that discuss the benefits, risk, alternative treatments, and quality of life had a median readability score of 12.5. Transcripts with low misinformation (85%) had a higher median readability index (12.6), than transcripts containing high misinformation (12.2). More than 20% of transcripts discussed shared decision-making. The median readability index for videos with a high Patient Education Materials Assessment Tool score (>75%) for understandability and actionability were both 12.6. CONCLUSION/CONCLUSIONS:Transcripts of POP YouTube videos are written at difficult levels with many transcripts exceeding the reading capabilities of the American population. The majority of good transcripts or transcripts with high quality content, low misinformation, shared decision-making, no commercial bias, and understandable and actionable content were written at a high school level or above. Efforts should be made to avoid complex terms when creating patient focused content and helping patients navigate to content of appropriate literacy online.
PMID: 33775787
ISSN: 1527-9995
CID: 4897502
Barriers and facilitators of germline genetic evaluation for prostate cancer
Loeb, Stacy; Li, Randall; Sanchez Nolasco, Tatiana; Byrne, Nataliya; Cheng, Heather H; Becker, Daniel; Leader, Amy E; Giri, Veda N
BACKGROUND:Genetic counseling and germline testing have an increasingly important role for patients with prostate cancer (PCa); however, recent data suggests they are underutilized. Our objective was to perform a qualitative study of the barriers and facilitators of germline genetic evaluation among physicians who manage PCa. METHODS:We conducted semi-structured interviews with medical oncologists, radiation oncologists, and urologists from different U.S. practice settings until thematic saturation was achieved at n = 14. The interview guide was based on the Tailored Implementation in Chronic Diseases Framework to identify key determinants of practice. Interview transcripts were independently coded by ≥2 investigators using a constant comparative method. RESULTS:The decision to perform or refer for germline genetic evaluation is affected by factors at multiple levels. Although patient factors sometimes play a role, the dominant themes in the decision to conduct germline genetic evaluation were at the physician and organizational level. Physician knowledge, coordination of care, perceptions of the guidelines, and concerns about cost were most frequently discussed as the main factors affecting utilization of germline genetic evaluation. CONCLUSIONS:There are currently numerous barriers to implementation of germline genetic evaluation for PCa. Efforts to expand physician education, to develop tools to enhance genetics in practice, and to facilitate coordination of care surrounding genetic evaluation are important to promote guideline-concordant care.
PMID: 34057231
ISSN: 1097-0045
CID: 4895032
Growth of the Twitter Presence of Academic Urology Training Programs and Its Catalysis by the COVID-19 Pandemic [Letter]
Manning, Emily; Calaway, Adam; Dubin, Justin M; Loeb, Stacy; Sindhani, Mohit; Kutikov, Alexander; Ponsky, Lee; Mishra, Kirtishri; Bukavina, Laura
PMID: 34006446
ISSN: 1873-7560
CID: 4954632
Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness
Kang, Stella K; Mali, Rahul D; Prabhu, Vinay; Ferket, Bart S; Loeb, Stacy
Background Active surveillance (AS) is the recommended treatment option for low-risk prostate cancer (PC). Surveillance varies in MRI, frequency of follow-up, and the Prostate Imaging Reporting and Data System (PI-RADS) score that would repeat biopsy. Purpose To compare the effectiveness and cost-effectiveness of AS strategies for low-risk PC with versus without MRI. Materials and Methods This study developed a mathematical model to evaluate the cost-effectiveness of surveillance strategies in a simulation of men with a diagnosis of low-risk PC. The following strategies were compared: watchful waiting, prostate-specific antigen (PSA) and annual biopsy without MRI, and PSA testing and MRI with varied PI-RADS thresholds for biopsy. MRI strategies differed regarding scheduling and use of PI-RADS score of at least 3, or a PI-RADS score of at least 4 to indicate the need for biopsy. Life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios were calculated by using microsimulation. Sensitivity analysis was used to assess the impact of varying parameter values on results. Results For the base case of 60-year-old men, all strategies incorporating prostate MRI extended QALYs and life-years compared with watchful waiting and non-MRI strategies. Annual MRI strategies yielded 16.19 QALYs, annual biopsy with no MRI yielded 16.14 QALYs, and watchful waiting yielded 15.94 QALYs. Annual MRI with PI-RADS score of at least 3 or of at least 4 as the biopsy threshold and annual MRI with biopsy even after MRI with negative findings offered similar QALYs and the same unadjusted life expectancy: 23.05 life-years. However, a PI-RADS score of at least 4 yielded 42% fewer lifetime biopsies. With a cost-effectiveness threshold of $100 000 per QALY, annual MRI with biopsy for lesions with PI-RADS scores of 4 or greater was most cost-effective (incremental cost-effectiveness ratio, $67 221 per QALY). Age, treatment type, risk of initial grade misclassification, and quality-of-life impact of procedural complications affected results. Conclusion The use of active surveillance (AS) with biopsy decisions guided by findings from annual MRI reduces the number of biopsies while preserving life expectancy and quality of life. Biopsy in lesions with PI-RADS scores of 4 or greater is likely the most cost-effective AS strategy for men with low-risk prostate cancer who are younger than 70 years. © RSNA, 2021 Online supplemental material is available for this article.
PMID: 34254851
ISSN: 1527-1315
CID: 4950412
Climate Change Impact of Virtual Urology Meetings [Letter]
Patel, Sunil H; Gallo, Kelsey; Becker, Russell; Borin, James; Loeb, Stacy
PMID: 33985798
ISSN: 1873-7560
CID: 5210712